Global mRNA Cancer Vaccines Market Set to Reach $6.71 Billion by 2030 Driven by Research, Investment, and Partnerships - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global mRNA Cancer Vaccines Market Opportunity & Clinical Pipeline Insight 2023" drug pipelines has been added to ResearchAndMarkets.com's offering.

The global mRNA cancer vaccines market is undergoing a paradigm shift, propelled by intense research, robust investment, and strategic alliances. This market upheaval is driven by the potential of mRNA technology to revolutionize cancer treatment, with companies racing to develop groundbreaking therapies that precisely target cancer cells.

Key Findings:

• Clinical Pipeline Insight: More than 40 mRNA cancer vaccines are under clinical trials.
• Clinical Development Stage: Phase 3 trials dominate the clinical landscape as of August 2023.
• Market Approval Status: No vaccines have been commercially approved as of August 2023.
• Comprehensive Pipeline Insight: Detailed information on vaccines by indication, company, country, and phase.
• Proprietary Technologies: Companies' innovative mRNA cancer vaccine technologies.
• Market Collaborations & Investments: Strategic partnerships and investment insights shaping the market landscape.

Innovation and Competition:

Pharmaceutical and biotechnology companies are channeling significant resources into advancing mRNA cancer vaccines from experimental stages to viable therapeutic options. The market is expanding through research and development investments, attracting both startups and established players. The allure of mRNA vaccines lies in their adaptability and potential to trigger robust immune responses against specific cancer antigens.

Strategic Collaborations:

Global pharmaceutical giants and biotechnology innovators are forming strategic alliances, shaping the commercial trajectory of mRNA cancer vaccines. Notable collaborations include BioNTech and Genentech, and Moderna and Merck, which combine expertise to expedite development, manufacturing, and distribution. Integrating mRNA vaccines into diverse oncology pipelines enhances overall market competitiveness.

Proprietary Platforms and Market Dynamics:

Companies are focusing on proprietary mRNA platforms targeting both common and rare cancer indications. For example, BioNTech's FixVac and iNeST platforms enable the development of personalized cancer vaccines. Competition fosters innovation, leading to improved production efficiency, pricing strategies, and distribution networks.

Challenges and Market Outlook:

The commercialization of mRNA cancer vaccines poses challenges including pricing, regulatory pathways, intellectual property, and safety concerns. Regulatory agencies' growing familiarity with mRNA technology, exemplified by COVID-19 vaccine approvals, may expedite future approvals. The global reach of mRNA cancer vaccines calls for understanding regional healthcare ecosystems and collaboration with stakeholders.

Promising Future Amid Complexities:

The global mRNA cancer vaccines market offers immense promise, yet requires careful navigation. Regulatory clearance, market acceptance, reimbursement policies, and supply chain management are vital factors for commercial success. As companies grapple with these complexities, the potential clinical impact remains evident, promising a transformative impact on the global fight against cancer.

Companies Mentioned

• Avstera Therapeutics
• BioNTech
• Combined Therapeutics
• CureVac
• EpiVax
• Immorna
• Immune Design
• MDimune
• Moderna Therapeutics
• NeoCura
• Orna Therapeutics
• pHion Therapeutics
• Regen BioPharma
• RNAimmune
• TransCode Therapeutics

Key Topics Covered:

1. mRNA Vaccines as Next Generation Cancer Immunotherapy

1.1 mRNA Vaccines Overview

1.2 mRNA Vaccines v/s Other Cancer Therapeutic Approaches

1.3 mRNA Vaccines v/s Other Vaccines

2. Global mRNA Cancer Vaccines Market Overview

2.1 Current Market Landscape

2.2 Future Clinical & Commercialization Opportunities

3. Global mRNA Cancer Vaccines Market Trends by Country

3.1 US

3.2 China

3.3 Australia

3.4 Europe

3.5 Canada

4. Global mRNA Cancer Vaccines Market Collaborations, Deals & Investments

5. Global mRNA Cancer Vaccines Market Clinical Landscape by Indication

5.1 Breast Cancer

5.2 Brain Cancer

5.3 Melanoma

5.4 Colorectal Cancer

5.5 Head & Neck Cancers

6. Global mRNA Cancer Vaccines Clinical Pipeline Overview

6.1 By Company

6.2 By Country

6.3 By Patient Segment

6.4 By Phase

6.5 By Priority Status

7. Global mRNA Cancer Vaccines Clinical Pipeline By Company, Indication & Phase

7.1 Research

7.2 Preclinical

7.3 Phase-I

7.4 Phase-I/II

7.5 Phase-II

7.6 Phase-II/III

7.7 Phase-III

8. Proprietary Technologies & Methodologies for RNA Cancer Vaccines Development

8.1 FixVac - BioNTech

8.2 iNeST - BioNTech

8.3 NanoReady - Samyang Holdings

8.4 CureVac Method - CureVac

8.5 mRNA platform - Moderna

8.6 NeoCura Ag - NeoCura

9. Competitive Landscape

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/vymrc

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900